BioCentury
ARTICLE | Company News

Anadys, Scriptgen, EMBL deal

July 3, 2000 7:00 AM UTC

Scriptgen changed its name to Anadys, and will focus on drug discovery for infectious diseases. Scriptgen issued shares to a group of investors involved in the formation of Anadys. Anadys also received an exclusive worldwide license to the laboratory's riboproteomics technology that characterizes and annotates RNA-protein interactions that affect RNA metabolism, in return for a five percent stake in the company. Anadys, which has products in preclinical development for chronic Hepatitis C virus, has collaborations with Aventis Pharma AG (Frankfurt, Germany), Eli Lilly and Co. (LLY, Indianapolis, Ind.) and Pharmacia Corp. (PHA, Peapack. N.J.). ...